NRAS and acute myeloid leukemia: In addition, there were more NRAS/KRAS mutations (30.0% vs. 10.7%, p = 0.037) and fewer IDH1/2 mutations (16.7% vs. 35.7%, p = 0.024) in the monocyte‐like AML group than in the nonmonocyte‐like AML group.